Señales en vivo de VACC | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 nov 2023 @ 16:00):

Stats
Volumen de hoy	163 052
Volumen promedio	731 881
Capitalización de mercado	192.73M
EPS	$0.220 ( 2023-11-09 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.45
ATR14	$0.559 (17.75%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-02	Pelletier Nadege	Buy	105 000	Share Option (Right to Buy)
2024-01-02	Griffiths Graham	Buy	96 500	Share Option (Right to Buy)
2024-01-02	Enright William	Buy	443 981	Share Option (Right to Buy)
2024-01-02	Brown Gemma	Buy	193 000	Share Option (Right to Buy)
2023-06-26	Scheeren Joseph	Buy	10 000	Ordinary Shares

INSIDER POWER
41.32
Last 95 transactions
Buy: 18 963 250 \| Sell: 20 685 755

Volumen Correlación

Largo: 0.07 (neutral)

Corto: 0.52 (weak)

Signal:(49.914) Neutral

Vaccitech plc Correlación

10 Correlaciones Más Positivas
SVOK	0.919
PAIC	0.901
FORE	0.872
RDUS	0.87
SVAC	0.858
RMRM	0.857
SPRT	0.835
TLGT	0.834
EPZM	0.829
IVA	0.828

10 Correlaciones Más Negativas
NETE	-0.908
BOCH	-0.876
RAVN	-0.866
AMRB	-0.862
HRMY	-0.852
SBBP	-0.847
MMAC	-0.843
CFMS	-0.835
SFST	-0.829
AEPPZ	-0.827

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Vaccitech plc Correlación - Moneda/Commodity

-0.46
( neutral )

-0.21
( neutral )

-0.41
( neutral )

-0.30
( neutral )

0.70
( moderate )

0.66
( moderate )

Vaccitech plc Finanzas

Annual	2022
Ingresos:	$44.70M
Beneficio Bruto:	$2.35M (5.26 %)
EPS:	$0.140

FY	2022
Ingresos:	$44.70M
Beneficio Bruto:	$2.35M (5.26 %)
EPS:	$0.140

FY	2021
Ingresos:	$268 000
Beneficio Bruto:	$268 000 (100.00 %)
EPS:	$-1 067.56

FY	2020
Ingresos:	$4.82M
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-371.62

Financial Reports:

No articles found.

Vaccitech plc

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.